Anti-human platelet antigen 1a (anti-HPA-1a) alloantibodies (Anti-HPA-1a)

Anti-human platelet antigen 1a (anti-HPA-1a) alloantibodies are pathogenic Immunoglobulin G (IgG) molecules that develop in HPA-1a-negative individuals, most commonly pregnant women, upon exposure to the HPA-1a antigen on fetal platelets (Winkelhorst et al., 2017, Blood Reviews). These antibodies specifically target the integrin beta-3 (GPIIIa) subunit of the platelet glycoprotein IIb/IIIa complex, which is the most frequent cause of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) in Caucasian populations (Peterson et al., 2013, Blood). In the context of pregnancy, maternal anti-HPA-1a antibodies cross the placenta via the neonatal Fc receptor (FcRn) and mediate the destruction of fetal platelets through opsonization and subsequent phagocytosis by splenic macrophages. This process results in severe fetal thrombocytopenia, posing a significant risk of intracranial hemorrhage (ICH), which can lead to permanent neurological disability or death (Lingman-Gerlin et al., 2023, NEJM). Therapeutic strategies currently under investigation include the use of FcRn inhibitors like nipocalimab to accelerate the clearance of maternal IgG and reduce its transfer to the fetus (ClinicalTrials.gov, NCT03842189). Additionally, prophylactic approaches using hyperimmune globulin or monoclonal anti-HPA-1a antibodies (e.g., RLYB212) are being developed to prevent maternal sensitization in at-risk pregnancies (Rallybio, 2024). Monitoring maternal antibody titers and HPA-1a genotyping are critical for identifying at-risk pregnancies and managing clinical outcomes.

Other names

Anti-HPA-1a antibodiesAnti-PlA1 antibodiesMaternal anti-HPA-1a alloantibodiesAnti-integrin beta-3 alloantibodies

The primary mechanisms of action for drugs targeting anti-HPA-1a alloantibodies include the inhibition of the neonatal Fc receptor (FcRn) to accelerate the degradation of pathogenic IgG (e.g., nipocalimab), and passive immunization using exogenous anti-HPA-1a antibodies to prevent maternal immune sensitization (e.g., RLYB212). Additionally, high-dose intravenous immunoglobulin (IVIG) is used to competitively inhibit placental antibody transfer and saturate Fc receptors on fetal macrophages.